SueWallSt

In this episode of Sue Wall Street: Holding Wall Street Accountable, we examine the securities class action lawsuit involving FS KKR Capital Corp. ($FSK). We break down allegations that the business development company overstated improvements in portfolio credit quality, restructuring efforts, valuation practices, and the sustainability of its shareholder distributions. Investors, income-focused s...

In this episode of Sue Wall Street: Holding Wall Street Accountable, we examine the securities class action lawsuit involving Globant ($GLOB). We break down allegations that the technology consulting giant promoted strong growth opportunities across Latin America while facing declining client demand, project cancellations, workforce reductions, wage freezes, employee unrest, and challenges tied to...

In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the securities class action lawsuit involving Graphic Packaging Holding Company ($GPK). We explore allegations that the company overstated the strength of its business model, inventory management strategy, demand outlook, and financial performance while facing growing inventory issues, declining volumes, rising cost...

In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the securities class action lawsuit involving LKQ Corporation ($LKQ). We explore allegations that LKQ promoted its Uni-Select and FinishMaster acquisition as a strategic growth driver with strong synergies and minimal integration risk while major customer losses and market share erosion were allegedly already occurr...

In this episode of Sue Wall Street: Holding Wall Street Accountable, we examine the securities class action lawsuit involving Phreesia ($PHR). We break down allegations that the healthcare technology company overstated visibility into future growth, pharmaceutical marketing demand, and the strength of its Network Solutions business before lowering fiscal 2027 revenue guidance. Investors, sharehold...

In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the securities class action lawsuit involving POET Technologies ($POET). We explore allegations surrounding PFIC tax status disclosures, a controversial executive interview, confidentiality obligations with Marvell and Celestial AI, canceled purchase orders, and a dramatic stock price decline. This deep dive is desi...

In this episode of Sue Wall Street: Holding Wall Street Accountable, we examine the securities class action lawsuit involving Regencell Bioscience Holdings ($RGC). We break down allegations surrounding extreme stock volatility, market manipulation risks, disclosure obligations, a Department of Justice investigation, and the company's dramatic share price surge despite having no approved products o...

In this episode of Sue Wall Street: Holding Wall Street Accountable, we break down the securities class action lawsuit against SES AI Corporation ($SES). Learn about allegations involving battery energy storage deals, AI technology claims, Molecular Universe, revenue growth projections, logistics issues, and the stock price decline. Perfect for investors, traders, shareholders, and anyone followin...

Dive into a compelling finance and investing podcast episode exploring Babcock & Wilcox Enterprises $BW and a high profile AI data center deal that captured Wall Street's attention. Perfect for investors, traders, and market enthusiasts, this deep dive examines artificial intelligence infrastructure, backlog growth, contract value questions, related party concerns, and investor risk. We break...

This episode dives into Upstart Holdings $UPST and a high stakes securities case where AI lending promises collided with unexpected model behavior. Built for investors, traders, and fintech watchers, we explore artificial intelligence credit models, loan approvals, macro sensitivity, and revenue volatility. Expect deep dive analysis, financial storytelling, and insights into algorithmic risk, fint...

This episode breaks down United Homes Group $UHG and a dramatic governance clash that turned a “maximize shareholder value” strategy into a steep discounted buyout. Built for investors, traders, and real estate market watchers, we explore board resignations, insider control risk, strategic review conflicts, and stock crashes. Expect deep dive analysis, financial storytelling, and insights into cor...

This episode dives into Stellantis $STLA and a massive business reset that stunned investors after bold electrification promises. Built for investors, traders, and auto industry watchers, we break down EV strategy risks, restructuring charges, earnings pressure, and stock volatility. Expect deep dive analysis, financial storytelling, and insights into electric vehicle demand, global auto trends, a...

This episode unpacks New Era Energy and Digital $NUAI and a complex securities case where AI data center ambitions collided with alleged permitting gaps and oil and gas liabilities. Built for investors, traders, and energy tech watchers, we explore regulatory risk, asset retirement obligations, related party concerns, and stock crashes. Expect deep dive analysis, financial storytelling, and insigh...

This episode dives into Medpace Holdings $MEDP and a high stakes securities case where strong guidance and “well behaved” cancellations collided with a disappointing book to bill miss. Built for investors, traders, and biotech service watchers, we break down CRO trends, backlog risk, cancellations, and revenue visibility. Expect deep dive analysis, financial storytelling, and insights into clinica...

This episode dives into Babcock and Wilcox $BW and a high stakes AI data center deal that sent the stock soaring before raising serious investor questions. Built for investors, traders, and energy and AI market watchers, we break down backlog growth, contract risk, related party concerns, and stock volatility. Expect deep dive analysis, financial storytelling, and insights into infrastructure play...

This episode breaks down Vital Farms $VITL and a supply chain disruption story tied to ERP system rollout risks, operational delays, and investor fallout. Built for investors, traders, and consumer goods watchers, we explore inventory systems, shipment slowdowns, retail shelf space loss, and earnings misses. Expect deep dive analysis, financial storytelling, and insights into execution risk and st...

This episode breaks down Pinterest $PINS and a high stakes securities case tied to ad revenue pressure, tariff impacts, and investor expectations. Built for investors, traders, and digital ad watchers, we explore retail advertiser pullbacks, platform monetization risk, restructuring signals, and stock volatility. Expect deep dive analysis, financial storytelling, and insights into social media sto...

This episode dives into Super Micro Computer $SMCI and a high stakes controversy where explosive AI server growth collided with alleged export control violations. Built for investors, traders, and tech market watchers, we break down AI infrastructure demand, data center growth, compliance risks, and stock crashes. Expect deep dive analysis, financial storytelling, and insights into semiconductors,...

This episode dives into ImmunityBio $IBRX and a biotech controversy where bold cancer cure claims collided with regulatory scrutiny. Built for investors, biotech traders, and market watchers, we break down FDA warning letters, drug approval limits, clinical hype, and stock drops. Expect deep dive analysis, biotech storytelling, and insights into regulatory risk, cancer therapies, and volatility. V...

This episode unpacks Gossamer Bio $GOSS and a biotech breakdown where trial design risks collided with investor expectations. Built for biotech investors, traders, and market watchers, we explore Phase three trials, placebo response impact, clinical data risk, and stock crashes. Expect deep dive analysis, biotech storytelling, and insights into FDA pathways, trial design flaws, and volatility. Vis...

This episode dives into Aldeyra Therapeutics $ALDX and a biotech story that flipped from clinical optimism to regulatory shock. Built for investors, biotech traders, and market watchers, we break down drug trials, FDA complete response letters, inconsistent data, and stock collapse risk. Expect deep dive analysis, biotech storytelling, and insights into clinical trials, FDA decisions, and volatili...

This episode breaks down Power Solutions International $PSIX and a shocking shift from booming data center demand to collapsing margins and investor fallout. Built for traders, investors, and market watchers, we explore earnings volatility, margin compression, production inefficiencies, and stock price crashes. Expect deep dive analysis, financial storytelling, and insights into growth stocks, dat...

This episode dives into Lufax Holdings $LU and a major accounting controversy involving restated financials, auditor concerns, and internal control failures. Built for investors, traders, and financial analysts, we break down earnings restatements, disclosure risks, audit red flags, and stock price reactions. Expect deep dive analysis, financial storytelling, and real insights into market trust an...

This episode dives into Hercules Capital $HTGC and a high stakes securities case questioning underwriting discipline, portfolio valuation, and deal sourcing practices. Built for investors, traders, and finance professionals, we break down net asset value N A V, private credit risk, software exposure, and market reactions. Expect deep dive analysis, investigative storytelling, and insights into BDC...

This episode unpacks Gemini Space Station $GEMI and a dramatic post IPO shift that stunned investors. Built for crypto traders, retail investors, and market watchers, we break down exchange growth narratives, prediction markets, layoffs, executive exits, and global pullbacks. Expect deep dive analysis, financial storytelling, and insights into IPO risk, crypto volatility, and stock market reaction...